Literature DB >> 8471819

Chronic pentamidine aerosol prophylaxis does not induce QT prolongation.

C Thalhammer1, J R Bogner, G Lohmöller.   

Abstract

Intravenous administration of pentamidine is known to cause long-QT syndrome (Torsade de pointes tachycardias and large QT prolongation) in rare cases and to cause small QT prolongation regularly. A similar pattern is seen with other drugs known to cause a long-QT syndrome. Pentamidine aerosol prophylaxis is commonly used to prevent Pneumocystis carinii pneumonia in HIV-infected persons. The goal of this study was to clarify whether pentamidine aerosol prophylaxis induces QT prolongation. We examined 100 patients receiving pentamidine aerosol prophylaxis at a rather high dose (300 mg biweekly) for at least 1 month (range 1-24) by determining the QT interval corrected for heart rate (QTc), blind for treatment. In a cross-sectional study, QTc was not different in 50 HIV-infected patients with chronic pentamidine aerosol prophylaxis (413 ms), 50 similar HIV-infected patients without pentamidine (407 ms), and 50 similar patients without HIV-infection and without pentamidine (407 ms). In a longitudinal study in another 50 HIV-infected patients, QTc was the same before (414 ms) and on long-term (median 9-month) pentamidine aerosol prophylaxis (414 ms). In contrast to the case with intravenous pentamidine, we found no QT prolongation and thereby no risk of long-QT syndrome with pentamidine aerosol prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471819     DOI: 10.1007/bf00184735

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  18 in total

1.  Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  K M Stein; H Haronian; G A Mensah; A Acosta; J Jacobs; P Kligfield
Journal:  Am J Cardiol       Date:  1990-10-01       Impact factor: 2.778

2.  Possible torsade in a patient with AIDS.

Authors:  E W Hancock
Journal:  Hosp Pract (Off Ed)       Date:  1990-07-15

3.  Incidence of QT interval prolongation during pentamidine therapy of Pneumocystis carinii pneumonia.

Authors:  K M Stein; C Fenton; A M Lehany; P M Okin; P Kligfield
Journal:  Am J Cardiol       Date:  1991-10-15       Impact factor: 2.778

4.  Acute renal failure after nebulised pentamidine.

Authors:  R F Miller; S Delany; S J Semple
Journal:  Lancet       Date:  1989-06-03       Impact factor: 79.321

5.  Inhaled pentamidine and hypoglycemia.

Authors:  J A Karboski; P J Godley
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

6.  [Treatment of mild to moderately severe Pneumocystis carinii pneumonia with cotrimoxazole versus pentamidine aerosol. Preliminary results of a prospective randomized therapy study].

Authors:  K Arasteh; W Heise; M L'age
Journal:  Med Klin (Munich)       Date:  1990-04

7.  Severe ventricular arrhythmia during pentamidine treatment of AIDS-associated Pneumocystis carinii pneumonia.

Authors:  T Loescher; K Loeschke; J Niebel
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

8.  Pentamidine-induced torsades de pointes: safe completion of therapy with inhaled pentamidine.

Authors:  A J Taylor; R W Hull; P E Coyne; R L Woosley; A H Eliasson
Journal:  Clin Pharmacol Ther       Date:  1991-06       Impact factor: 6.875

9.  Comparison of plasma concentrations of aerosolized pentamidine in nonventilated and ventilated patients with pneumocystosis.

Authors:  P M Girard; B Clair; A Certain; R Bidault; S Matheron; B Regnier; R Farinotti
Journal:  Am Rev Respir Dis       Date:  1989-12

10.  Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity.

Authors:  M R Bibler; T C Chou; R J Toltzis; P A Wade
Journal:  Chest       Date:  1988-12       Impact factor: 9.410

View more
  1 in total

1.  Pentamidine reduces hERG expression to prolong the QT interval.

Authors:  Jason S Cordes; Zhuoqian Sun; David B Lloyd; Jenifer A Bradley; Alan C Opsahl; Mark W Tengowski; Xian Chen; Jun Zhou
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.